Hanbing Li

Prof. Hanbing Li

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009
Verified
Journal Article
Closed access
HLHanbing Li
Hanbing Li
DYDan Yan
Dan Yan
CJCheng Jin
Cheng Jin
JWJia-Bo Wang
Jia-Bo Wang
LWLi Wei
Li Wei
JCJun-Ling Cao
Jun-Ling Cao

18 February 2026 in Transition Metal Chemistry
Verified
Journal Article
Closed access
PDF file
XWXia Wang
Xia Wang
HLHanbing Li
Hanbing Li
DCDi Cheng
Di Cheng
MCMeng-Meng Cao
Meng-Meng Cao
WYWen-Ke Yang
Wen-Ke Yang
TZTan-Peng Zhou
Tan-Peng Zhou

1 January 2026 in International Journal of Analytical Chemistry
Verified
Journal Article
Open access
JSJunhui Song
Junhui Song
GLGen Lin Li
Gen Lin Li
SWSu-Hui Wu
Su-Hui Wu
HLHanbing Li
Hanbing Li
Objective: This review provides a comprehensive summary of recent advancements in metabolomic analysis within traditional Chinese medicine (TCM) for the treatment of diabetes mellitus. It focuses on the standardized profiling of syndrome‐specific metabolites, the identification of bioactive compounds using high‐throughput techniques, and the elucidation of mechanisms based on metabolic pathways. The review aims to establish a reproducible analytical framework for TCM metabolomics, which includes identifying active compounds, clarifying mechanisms of action, and assessing therapeutic efficacy. By synthesizing the current body of evidence, this work seeks to provide a scientific foundation for future research, enhance the integration of metabolomics with TCM theory, and support the modernization and global acceptance of TCM in diabetes care. Ultimately, it addresses key challenges, such as the subjective nature of syndrome diagnosis and the complexity of multicomponent interactions. Subjects and Methods: A systematic review of the peer‐reviewed literature was conducted using PubMed, Web of Science, CNKI, and Wanfang Data for studies published up to 2025. The review included original research, reviews, and clinical trials that utilized metabolomic techniques (LC‐MS/MS, GC‐MS, and 600 MHz NMR) and standardized workflows (sample preparation, derivatization, instrument analysis, and data processing) in diabetic models. The qualitative synthesis focused on high‐throughput analytics, multivariate statistics (principal component analysis/partial least squares‐discriminant analysis [PCA/PLS‐DA] with 7‐fold cross‐validation and CV‐ANOVA, p < 0.05), and metabolite identification via the human metabolome database (HMDB)/METLIN metabolite database (mass error < 5 ppm); furthermore, these data were integrated with network pharmacology or multiomics approaches. Results: Metabolomics has revealed distinct metabolic profiles for TCM syndromes. Specifically, the Qi‐Yin deficiency (QYD) syndrome is associated with altered levels of L‐glutamate (variable importance in projection [VIP] > 1, p < 0.05) and arachidonic acid (limit of detection [LOD] = 0.01–0.1 ng/mL), as well as the accumulation of turbid toxins involving pantothenate and CoA biosynthesis. Key hypoglycemic bioactive compounds, such as epicatechin and berberine, were identified using ultraperformance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry (UPLC‐QTOF‐MS), with a mass error of < 5 ppm. Mechanistic studies have shown that TCM works through multiple pathways, including improving insulin resistance (e.g., mulberry leaves modulating amino acid/lipid metabolism); protecting β‐cells (e.g., timosaponin BII restoring phosphatidylserine levels); regulating glycolipid metabolism (e.g., Huanglian decoction influencing energy‐related metabolites); modulating gut microbiota (e.g., Gegen Qinlian decoction altering bile acids and short‐chain fatty acids); and preventing complications (e.g., Sophora flavescens affecting oxidative stress through glycerophospholipid metabolism). Furthermore, metabolomics enabled efficacy comparisons, highlighting improved outcomes with nanoformulations or exercise‐TCM combinations. Conclusions: Metabolomics provides a powerful approach to objectively assess TCM syndromes, clarify multitarget mechanisms, and comprehensively evaluate efficacy in diabetes treatment, which aligns well with TCM’s holistic principles. Despite existing challenges, such as the lack of standardized TCM syndrome classification and the complexity of metabolomic data (e.g., overlapping metabolite signals and multipathway crosstalk), future studies should focus on rigorous experimental designs, standardized protocols, and multiomics integration to promote biomarker discovery, personalized TCM, and its global integration into diabetes management.

6 July 2026 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
YWYu Wang
Yu Wang
CWCheng-Bao Wang
Cheng-Bao Wang
HLHanbing Li
Hanbing Li
AZAo Zhang
Ao Zhang
C 38 H 40 ZnN 10 O 4 , monoclinic, C 2/ c , a = 16.6873(6) Å, b = 13.5546(4) Å, c = 16.7498(6) Å, β = 111.484(4)°, Z = 4, V = 3525.4(2) Å 3 , R gt ( F ) = 0.0408, wR ref ( F 2 ) = 0.1072, T = 150 K.

10 October 2024 in Zeitschrift für Kristallographie - New Crystal Structures
Verified
Journal Article
Open access
PDF file
TBTongyu Bai
Tongyu Bai
HLHanbing Li
Hanbing Li
MCMengmeng Cao
Mengmeng Cao
XWXia Wang
Xia Wang
C36H32Cu2N24Cl4, monoclinic, P21/c (no. 14), a = 17.6099(4) Å, b = 8.13871(18) Å, c = 14.8084(3) Å, β = 91.6878(19)°, Z = 2, V = 2,121.45(8) Å3, R gt(F) = 0.0549, wR ref(F 2) = 0.1597, T = 293(2) K.